LIVE WEBINAR: Monday, March 1, 2021, 5:00 PM – 6:00 PM Eastern Time

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Renal Cell Carcinoma (Part 2 of a 3-Part Series)

A CME Webinar Series Held in Conjunction with the 2021 Genitourinary Cancers Symposium

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Monday, March 1st for this CME-accredited webinar
5:00 PM – 6:00 PM Eastern Time


Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, Urologic Cancer Research and Treatment Center
Texas Oncology
Charles A Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine
Texas A&M HSC College of Medicine
Dallas, Texas

Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by an educational grant from Exelixis Inc.

Not an official event of the 2021 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2021 Genitourinary Cancers Symposium.

Monday, March 1, 2021
5:00 PM – 6:00 PM Eastern Time
Live CME-accredited webinar

Topics to Be Discussed

  • Current Front-Line Management Strategies for Patients with Advanced Renal Cell Carcinoma (RCC)
  • Novel Combination Approaches Under Investigation for Patients with Advanced RCC
  • Selection and Sequencing of Therapies for Patients with Relapsed/Refractory RCC
  • Management of Toxicities and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors and TKIs for Advanced RCC

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Effectively apply evidence-based research findings and other clinical and biologic factors in the best practice selection of first-line therapy for patients with metastatic renal cell carcinoma (mRCC).
  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for patients with mRCC, and develop strategies to appropriately integrate this approach into the care of these individuals.
  • Appraise available clinical trial data evaluating the use of anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for patients with previously untreated mRCC, and counsel individuals with the disease regarding the risks and benefits of these novel regimens.
  • Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapeutic approaches.
  • Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive care plans for patients with RCC undergoing treatment with these agents and regimens.
  • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC, and, where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Hutson has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr PowlesAdvisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Exelixis Inc.